Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : AFT Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries
Details : Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.
Product Name : Maxigesic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : AFT Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
